FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783293894> ?p ?o ?g. }

• W2783293894 endingPage "128" @default.
• W2783293894 startingPage "127" @default.
• W2783293894 abstract "INTRODUCTION: Chagas disease, caused by the parasite Trypanosoma cruzi , affects more than seven million people worldwide and it is considered by the World Health Organization (WHO) a neglected tropical disease (1). About one third of Chagas patients develop gastrointestinal disorders, such as dysphagia and achalasia. Management of the disease focuses on symptom improvement and drugs that relax the lower esophageal sphincter pressure (LESP), such as isosorbide and nifedipine. However, the use of these therapies is doubtful because of their side effects and palliative approach (2). The objective of this systematic review is to assess the effectiveness of isosorbide and nifedipine on gastrointestinal manifestation of Chagas disease. METHODS: We searched MEDLINE, EMBASE and LILACS databases to retrieve potentially relevant articles from inception to December 2016. Inclusion criteria: clinical trials, cohorts or cross-sectional design; adults (>18 years old); assessment of effects of isosorbide or nifedipine on gastrointestinal symptoms in Chagas patients. Two reviewers independently screened titles and abstracts, selected eligible studies and extracted data from each study. PROSPERO registration number: CRD42017055143. RESULTS: Eight studies were included (two case series, two clinical trials and four crossovers). Three studies evaluated the effect of isosorbide in LESP and three in esophageal emptying. All of them found that isosorbide rapidly reduces LESP and increases esophageal emptying rates, improving dysphagia. However, several patients reported collateral effects, such as gastroesophageal reflux, headaches and dizziness. One study evaluated the effect of nifedipine on LESP and one on esophageal emptying. Nifedipine decreased LESP, but there was no effect on esophageal emptying. CONCLUSIONS: The available evidence shows isosorbide is effective in the management of gastrointestinal symptoms. Frequently health care of Chagas disease patients is delivered by primary care physicians. So, information on effectiveness of interventions can be aggregated to clinical guidelines, having an important value to inform general practitioners on the decision-making process regarding treatment of this group of patients, avoiding referencing to a specialized care." @default.
• W2783293894 created "2018-01-26" @default.
• W2783293894 creator A5002861419 @default.
• W2783293894 creator A5035934697 @default.
• W2783293894 creator A5038528759 @default.
• W2783293894 creator A5064666151 @default.
• W2783293894 creator A5069024230 @default.
• W2783293894 creator A5074453447 @default.
• W2783293894 date "2017-01-01" @default.
• W2783293894 modified "2023-10-18" @default.
• W2783293894 title "PP117 Isosorbide And Nifedipine In Chagas Patients: A Systematic Review" @default.
• W2783293894 cites W1984194904 @default.
• W2783293894 doi "https://doi.org/10.1017/s0266462317002768" @default.
• W2783293894 hasPublicationYear "2017" @default.
• W2783293894 type Work @default.
• W2783293894 sameAs 2783293894 @default.
• W2783293894 citedByCount "0" @default.
• W2783293894 crossrefType "journal-article" @default.
• W2783293894 hasAuthorship W2783293894A5002861419 @default.
• W2783293894 hasAuthorship W2783293894A5035934697 @default.
• W2783293894 hasAuthorship W2783293894A5038528759 @default.
• W2783293894 hasAuthorship W2783293894A5064666151 @default.
• W2783293894 hasAuthorship W2783293894A5069024230 @default.
• W2783293894 hasAuthorship W2783293894A5074453447 @default.
• W2783293894 hasConcept C126322002 @default.
• W2783293894 hasConcept C141071460 @default.
• W2783293894 hasConcept C177713679 @default.
• W2783293894 hasConcept C2779066535 @default.
• W2783293894 hasConcept C2780596822 @default.
• W2783293894 hasConcept C519063684 @default.
• W2783293894 hasConcept C535046627 @default.
• W2783293894 hasConcept C71924100 @default.
• W2783293894 hasConceptScore W2783293894C126322002 @default.
• W2783293894 hasConceptScore W2783293894C141071460 @default.
• W2783293894 hasConceptScore W2783293894C177713679 @default.
• W2783293894 hasConceptScore W2783293894C2779066535 @default.
• W2783293894 hasConceptScore W2783293894C2780596822 @default.
• W2783293894 hasConceptScore W2783293894C519063684 @default.
• W2783293894 hasConceptScore W2783293894C535046627 @default.
• W2783293894 hasConceptScore W2783293894C71924100 @default.
• W2783293894 hasIssue "S1" @default.
• W2783293894 hasLocation W27832938941 @default.
• W2783293894 hasOpenAccess W2783293894 @default.
• W2783293894 hasPrimaryLocation W27832938941 @default.
• W2783293894 hasRelatedWork W1982584050 @default.
• W2783293894 hasRelatedWork W2165457348 @default.
• W2783293894 hasRelatedWork W2423233162 @default.
• W2783293894 hasRelatedWork W2468128494 @default.
• W2783293894 hasRelatedWork W2581699428 @default.
• W2783293894 hasRelatedWork W2730020983 @default.
• W2783293894 hasRelatedWork W2983695971 @default.
• W2783293894 hasRelatedWork W3049286183 @default.
• W2783293894 hasRelatedWork W4206618956 @default.
• W2783293894 hasRelatedWork W4252207178 @default.
• W2783293894 hasVolume "33" @default.
• W2783293894 isParatext "false" @default.
• W2783293894 isRetracted "false" @default.
• W2783293894 magId "2783293894" @default.
• W2783293894 workType "article" @default.